NervGen Pharma Corp.
NGEN.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.72M | 6.76M | 6.63M | 7.45M | 7.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.18M | 16.90M | 14.20M | 13.37M | 13.17M |
| Operating Income | -18.18M | -16.90M | -14.20M | -13.37M | -13.17M |
| Income Before Tax | -17.44M | -17.62M | -16.99M | -14.82M | -16.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.44 | -17.62 | -16.99 | -14.82 | -16.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.44M | -17.62M | -16.99M | -14.82M | -16.56M |
| EBIT | -18.18M | -16.90M | -14.20M | -13.37M | -13.17M |
| EBITDA | -18.14M | -16.86M | -14.14M | -13.29M | -13.08M |
| EPS Basic | -0.25 | -0.27 | -0.27 | -0.25 | -0.28 |
| Normalized Basic EPS | -0.16 | -0.17 | -0.17 | -0.16 | -0.17 |
| EPS Diluted | -0.25 | -0.27 | -0.27 | -0.25 | -0.28 |
| Normalized Diluted EPS | -0.16 | -0.17 | -0.17 | -0.16 | -0.17 |
| Average Basic Shares Outstanding | 270.22M | 259.79M | 249.14M | 238.40M | 237.16M |
| Average Diluted Shares Outstanding | 270.22M | 259.79M | 249.14M | 238.40M | 237.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |